Structure/Function of Terminal Complement Proteins

末端补体蛋白的结构/功能

基本信息

项目摘要

DESCRIPTION (provided by applicant): The long-term objective of this project is to understand molecular details of the formation and function of human C5b-9, the cytolytic complex of complement referred to as the "membrane attack complex" or MAC. MAC is composed of C5b, C6, C7, C8 and C9. Among these components, C6, C7, the C8alpha and C8beta subunits, and C9 are homologous whereas C8gamma has the distinction of being the only lipocalin in the complement system. This project will focus on C8 as a model system to identify structure-function relationships within the MAC proteins. Emphasis will be on C8gamma and the possibility it has a previously unrecognized role in MAC formation and function. Specific aims are: (1) to characterize the ligand binding properties of C8gamma. The C8gamma crystal structure displays a typical lipocalin fold with a distinct binding site for an as yet unidentified small molecule. Studies will focus on fatty acids and related compounds as potential ligands to determine if C8gamma has the capacity to bind membrane lipid, e.g. glycerophospholipids and LPS, or possibly soluble proinflammatory molecules released in the vicinity of the MAC; (2) to test the hypothesis that C8gamma enhances MAC activity through direct interaction with membrane-associated lipid. Mutants in which ligand binding is restricted will be prepared and characterized with respect to retention/loss of ability to enhance MAC hemolytic and bactericidal activities. Positive results would suggest C8gamma may be involved in inducing MAC-mediated responses in nucleated cells; (3) to identify functionally important binding sites in C8. The site on C8gamma that binds C8alpha will be identified using chimeric constructs of C8gamma and its structural homologue NGAL, and testing these for C8alpha binding. The region of C8beta which binds the intermediate MAC complex C5b-7 will use C8alpha / C8beta chimeras and C8beta deletion mutants to determine the role of the modules; (4) to produce fragments of the MAC proteins for crystallization and structural studies. Segments of C8alpha and C8beta will be produced recombinantly and by proteolytic digestion of serum-derived C8. The former approach will emphasize the central MACPF segment because it is likely to be self-folding domain that can be expressed. The latter approach will take advantage of scale. When complete, results will provide new insight into mechanisms by which the MAC proteins interact with each other and the target cell membrane. Such information will facilitate design and development of therapeutically useful analogues of MAC and regulators of MAC lytic and stimulatory functions. Because of the uniqueness of the MAC proteins and their function, information obtained will contribute to an understanding of protein structure-function relationships in general.
描述(由申请人提供):该项目的长期目标是了解人体C5b-9的形成和功能的分子细节,C5b-9是补体的细胞溶解复合物,称为“膜攻击复合物”或MAC。MAC由C5b, C6, C7, C8和C9组成。在这些成分中,C6、C7、c8 α和c8 β亚基和C9是同源的,而c8 γ的区别在于它是补体系统中唯一的脂质体蛋白。本项目将重点关注C8作为模型系统,以确定MAC蛋白的结构-功能关系。重点将放在c8γ和它在MAC形成和功能中可能具有以前未被认识到的作用。具体目的是:(1)表征C8gamma的配体结合特性。c8γ晶体结构显示出典型的脂质体折叠,具有一个尚未确定的小分子的独特结合位点。研究将集中于脂肪酸和相关化合物作为潜在的配体,以确定C8gamma是否具有结合膜脂的能力,例如甘油磷脂和LPS,或可能在MAC附近释放的可溶性促炎分子;(2)验证C8gamma通过与膜相关脂质的直接相互作用增强MAC活性的假设。将制备配体结合受到限制的突变体,并以其保留/丧失增强MAC溶血和杀菌活性的能力为特征。阳性结果提示c8γ可能参与诱导有核细胞中mac介导的反应;(3)识别C8中功能重要的结合位点。将使用C8gamma及其结构同源物NGAL的嵌合结构确定C8alpha上与C8alpha结合的位点,并测试这些位点是否与C8alpha结合。结合中间MAC复合物C5b-7的C8beta区域将使用C8alpha / C8beta嵌合体和C8beta缺失突变体来确定模块的作用;(4)制备MAC蛋白的片段,用于结晶和结构研究。c8α和c8β片段将通过重组和血清来源的C8蛋白水解消化产生。前一种方法将强调中心的MACPF片段,因为它很可能是可以表达的自折叠域。后一种方法将利用规模优势。当完成时,结果将为MAC蛋白相互作用和靶细胞膜的机制提供新的见解。这些信息将有助于设计和开发治疗上有用的MAC类似物以及MAC分解和刺激功能的调节因子。由于MAC蛋白及其功能的独特性,所获得的信息将有助于理解蛋白质结构-功能的一般关系。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

JAMES M SODETZ其他文献

JAMES M SODETZ的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('JAMES M SODETZ', 18)}}的其他基金

SMALL INSTRUMENTATION GRANT
小型仪器补助金
  • 批准号:
    3523593
  • 财政年份:
    1991
  • 资助金额:
    $ 27.21万
  • 项目类别:
SMALL INSTRUMENTATION GRANT
小型仪器补助金
  • 批准号:
    3523420
  • 财政年份:
    1990
  • 资助金额:
    $ 27.21万
  • 项目类别:
STRUCTURE AND FUNCTION OF TERMINAL COMPLEMENT PROTEINS
末端补体蛋白的结构和功能
  • 批准号:
    2181724
  • 财政年份:
    1989
  • 资助金额:
    $ 27.21万
  • 项目类别:
STRUCTURE AND FUNCTION OF TERMINAL COMPLEMENT PROTEINS
末端补体蛋白的结构和功能
  • 批准号:
    2518959
  • 财政年份:
    1989
  • 资助金额:
    $ 27.21万
  • 项目类别:
STRUCTURE/FUNCTION OF TERMINAL COMPLEMENT PROTEINS
末端补体蛋白的结构/功能
  • 批准号:
    6385957
  • 财政年份:
    1989
  • 资助金额:
    $ 27.21万
  • 项目类别:
Structure/Function of Terminal Complement Proteins
末端补体蛋白的结构/功能
  • 批准号:
    7071856
  • 财政年份:
    1989
  • 资助金额:
    $ 27.21万
  • 项目类别:
Structure/Function of Terminal Complement Proteins
末端补体蛋白的结构/功能
  • 批准号:
    6611330
  • 财政年份:
    1989
  • 资助金额:
    $ 27.21万
  • 项目类别:
Structure/Function of Terminal Complement Proteins
末端补体蛋白的结构/功能
  • 批准号:
    6748098
  • 财政年份:
    1989
  • 资助金额:
    $ 27.21万
  • 项目类别:
Structure/Function of Terminal Complement Proteins
末端补体蛋白的结构/功能
  • 批准号:
    7925526
  • 财政年份:
    1989
  • 资助金额:
    $ 27.21万
  • 项目类别:
STRUCTURE AND FUNCTION OF TERMINAL COMPLEMENT PROTEINS
末端补体蛋白的结构和功能
  • 批准号:
    2181723
  • 财政年份:
    1989
  • 资助金额:
    $ 27.21万
  • 项目类别:

相似海外基金

Development of Targeted Antipseudomonal Bactericidal Prodrugs
靶向抗假单胞菌杀菌前药的开发
  • 批准号:
    10678074
  • 财政年份:
    2023
  • 资助金额:
    $ 27.21万
  • 项目类别:
Propagation and Characterization of Phage Related to Human Growth
与人类生长相关的噬菌体的繁殖和表征
  • 批准号:
    10668108
  • 财政年份:
    2023
  • 资助金额:
    $ 27.21万
  • 项目类别:
Project 2: Targeting Gram-positive Cell Envelope Assembly
项目 2:靶向革兰氏阳性细胞包膜组装
  • 批准号:
    10699955
  • 财政年份:
    2022
  • 资助金额:
    $ 27.21万
  • 项目类别:
Biomimetic Peptide Aerosols for Rapid Clearance of Pulmonary MDR Tuberculosis
用于快速清除耐多药肺结核的仿生肽气雾剂
  • 批准号:
    10344596
  • 财政年份:
    2021
  • 资助金额:
    $ 27.21万
  • 项目类别:
Biomimetic Peptide Aerosols for Rapid Clearance of Pulmonary MDR Tuberculosis
用于快速清除耐多药肺结核的仿生肽气雾剂
  • 批准号:
    10530676
  • 财政年份:
    2021
  • 资助金额:
    $ 27.21万
  • 项目类别:
A Label-free, Ultra-High-Throughput Bacteriolysis Droplet Screening Platform (KillerDrop)
无标记、超高通量溶菌液滴筛选平台 (KillerDrop)
  • 批准号:
    BB/T011777/1
  • 财政年份:
    2020
  • 资助金额:
    $ 27.21万
  • 项目类别:
    Research Grant
Mechanistic Insights into Activation and Regulation of Interferon-inducible GTPase GBP2
干扰素诱导型 GTP 酶 GBP2 激活和调节的机制见解
  • 批准号:
    10615060
  • 财政年份:
    2020
  • 资助金额:
    $ 27.21万
  • 项目类别:
Mechanistic Insights into Activation and Regulation of Interferon-inducible GTPase GBP2
干扰素诱导型 GTP 酶 GBP2 激活和调节的机制见解
  • 批准号:
    10393611
  • 财政年份:
    2020
  • 资助金额:
    $ 27.21万
  • 项目类别:
Mechanistic Insights into Activation and Regulation of Interferon-inducible GTPase GBP2
干扰素诱导型 GTP 酶 GBP2 激活和调节的机制见解
  • 批准号:
    10052724
  • 财政年份:
    2020
  • 资助金额:
    $ 27.21万
  • 项目类别:
Mechanistic Insights into Activation and Regulation of Interferon-inducible GTPase GBP2
干扰素诱导型 GTP 酶 GBP2 激活和调节的机制见解
  • 批准号:
    10166764
  • 财政年份:
    2020
  • 资助金额:
    $ 27.21万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了